Verition Fund Management LLC Ikena Oncology, Inc. Transaction History

Verition Fund Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.24 - $1.82 $1.24 Million - $1.82 Million	-999,390 Reduced 88.08%	135,297 $223,000
Q1 2024 May 14, 2024	SELL	$1.27 - $2.0 $238,391 - $375,420	-187,710 Reduced 14.19%	1,134,687 $1.61 Million
Q4 2023 Feb 14, 2024	SELL	$1.33 - $4.4 $531,058 - $1.76 Million	-399,292 Reduced 23.19%	1,322,397 $2.61 Million
Q3 2023 Nov 14, 2023	BUY	$4.09 - $6.43 $2.7 Million - $4.25 Million	660,581 Added 62.25%	1,721,689 $7.45 Million
Q2 2023 Aug 14, 2023	SELL	$3.5 - $7.31 $1.87 Million - $3.91 Million	-534,833 Reduced 33.51%	1,061,108 $6.96 Million
Q1 2023 May 15, 2023	BUY	$2.62 - $4.97 $40,782 - $77,363	15,566 Added 0.98%	1,595,941 $5.51 Million
Q4 2022 Feb 14, 2023	BUY	$2.0 - $3.7 $562,240 - $1.04 Million	281,120 Added 21.64%	1,580,375 $4.2 Million
Q3 2022 Nov 14, 2022	BUY	$3.46 - $6.0 $959,682 - $1.66 Million	277,365 Added 27.14%	1,299,255 $4.61 Million
Q2 2022 Aug 15, 2022	BUY	$3.23 - $7.4 $3.3 Million - $7.56 Million	1,021,890 New	1,021,890 $4.53 Million

30.6M

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $56.9M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.